Age Related Macular Degeneration News and Research

RSS

QLT reports final 24-month results from Phase II RADICAL study in patients with wet AMD

QLT Inc. today announced final 24-month results from the Phase II RADICAL study (Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In Combination for AMD Lesions) in patients with exudative (wet) age-related macular degeneration. The purpose of the study was to determine if Visudyne® combined with Lucentis® reduced retreatment rates compared with Lucentis monotherapy, while maintaining similar vision outcomes and an acceptable safety profile.

22 Jun 2010

OXiGENE reports encouraging data from ZYBRESTAT program at Glaucoma and Retinopathies 2010 conference

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that the company presented an update on its ZYBRESTAT ophthalmology program, including encouraging preclinical data showing that the company's topical formulation achieved target retina/choroid concentrations with minimal systemic exposure.

22 Jun 2010

WSJ: Study on eye medicine reveals possible savings for Medicare

The Wall Street Journal reports that Medicare could save $500 million a year by switching from one type of eye medicine to another, both made by Genentech, "according to a draft study by federal officials and a University of Miami eye doctor.

18 Jun 2010

ACT awarded patent for production processes of RPE cells from hESCs

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it has been issued U.S. Patent Number 7736896, which is broadly directed to processes developed by ACT scientists for the production of retinal pigment epithelial (RPE) cells from human embryonic stem cells (hESCs).

17 Jun 2010

Final results from Visudyne Phase IIIb DENALI study presented at World Ophthalmology Congress

QLT Inc. today announced that final results from the Novartis-sponsored Phase IIIb DENALI study were presented on June 8, 2010 during the World Ophthalmology Congress in Berlin. DENALI was a 24-month randomized, double-masked, multicenter trial in patients with subfoveal choroidal neovascularization secondary to wet age-related macular degeneration (all lesion types).

16 Jun 2010

SQNM first-quarter 2010 total revenues up 22%: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Sequenom Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

15 Jun 2010

Bevacizumab effective for treatment of wet AMD: Study

An inexpensive, but unlicensed drug to help prevent severe sight loss in older people has been shown to be safe and effective, finds a study published on bmj.com today.

11 Jun 2010

USPTO grants ISCO patent to International Stem Cell's hpSC

International Stem Cell Corporation, www.intlstemcell.com, announced today that the United States Patent and Trademark Office has granted ISCO patent number 7,732,202, the first of several pending patents relating to its development of human parthenogenetic Stem Cells. Human parthenogenetic stem cells are a new type of pluripotent stem cell that allows immune matching to potentially solve critical immune rejection problems, and does not involve the ethical issues that surround the use of fertilized human embryos.

8 Jun 2010

Ranibizumab improves vision in patients with visual impairment due to DME: RESTORE study

Results from a new major diabetes eye health study may have the potential to change the way vision loss due to diabetic macular edema, a serious and devastating complication of diabetes, is treated. One year results from the RESTORE study show that 37 per cent of patients treated with ranibizumab only and 43 per cent of those treated with ranibizumab plus laser therapy, had a significant improvement in visual acuity of 10 letters or more on an eye chart, compared to 16 per cent of patients treated with laser alone - the current standard treatment for visual impairment due to DME.

7 Jun 2010

Adeona completes 50% enrollment in Part 2 CopperProof-2 study of oral zinc cysteine for Alzheimer's Disease

Adeona Pharmaceuticals, Inc. announced the completion of 50% enrollment in Part 2 of its clinical study, A Prospective, Randomized, Double Blind Trial of a Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease (CopperProof-2).

7 Jun 2010

New book to prevent Age-Related Macular Degeneration

A new prevention tool is now available, in both French and English, at local bookstores and pharmacies. Dr. Jean-Daniel Arbour and Dr. Pierre Labelle of the Universit- de Montr-al Department of Ophthalmology, along with two colleagues from France, have authored a new book to prevent vision loss, AMD: Age-Related Macular Degeneration (Annika Parance Publisher; 121 pages). Written to educate readers about the importance of vision health, the book provides clear explanations on the causes, consequences and treatments of AMD.

26 May 2010

Results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 to be presented at ASCO 2010

TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and ophthalmology, announced today that results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 will be presented at the annual meeting of the American Society of Clinical Oncology on June 5-7, 2010 in Chicago, IL.

19 May 2010

MUHC's Henry C. Witelson Ocular Pathology Laboratory celebrates tenth anniversary

The Burnier International Ocular Pathology Society is holding a Scientific Colloquium in Montreal today to mark the tenth anniversary of the McGill University Health Centre's Henry C. Witelson Ocular Pathology Laboratory. The lab is an internationally reputed centre for the study and treatment of eye diseases and is leading a global network for the sharing of healthcare knowledge and expertise.

7 May 2010

Resolvyx presents new data on RX-10001 for corneal herpes simplex virus infection at ARVO 2010

Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced the presentation of data on its novel resolvins for the treatment of both ocular surface diseases and retinal diseases at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale, Florida, being held May 2-6, 2010.

7 May 2010

Pfizer presents data on in vivo activity of PF-04523655 siRNA drug candidate at ARVO annual meeting

Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today that researchers from Pfizer, Inc. presented data on in vivo activity of PF-04523655 at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, being held May 2-6, 2010 in Fort Lauderdale.

7 May 2010

StemCells first-quarter total revenue up 307%

StemCells, Inc., a leading stem cell technology company with the dual focus of novel therapeutics and innovative research products, today reported financial results for the first quarter ended March 31, 2010 and recent business highlights.

5 May 2010

Acucela to present data on ACU-4429 oral visual cycle modulator for dry AMD at Retina International meeting

Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that Ryo Kubota, M.D., Ph.D., Acucela's chairman, president and chief executive officer, has been invited to participate in Retina International's annual Scientific & Medical Advisory Board meeting being held in Fort Lauderdale, Florida on May 3, 2010.

3 May 2010

Report shows increasing rates of AMD among Asians

The May issue of Ophthalmology, the journal of the American Academy of Ophthalmology, includes a surprising, first report on increasing rates of age-related macular degeneration among Asians, and describes an innovative "bypass" laser surgery that may help many people with central retinal vein occlusion avoid serious vision loss.

3 May 2010

Latinos have higher rates of developing visual impairment than non-Hispanic whites: Researchers

Latinos have higher rates of developing visual impairment, blindness, diabetic eye disease, and cataracts than non-Hispanic whites, researchers found. These are the first estimates of visual impairment and eye disease development in Latinos, the largest and fastest growing minority population in the United States.

3 May 2010

IRIDEX commences commercial shipment of IQ 532 laser systems

IRIDEX Corporation, today announced the commencement of commercial shipment of the IQ 532 laser systems. The IQ 532 is a high-power, 532 nm, dual port multi-purpose laser system for use by ophthalmologists to treat sight-threatening eye diseases such as diabetic retinopathy, age-related macular degeneration and glaucoma; and for use by otolaryngologists to correct certain types of conductive hearing loss.

30 Apr 2010

Age Related Macular Degeneration News and Research

QLT reports final 24-month results from Phase II RADICAL study in patients with wet AMD

OXiGENE reports encouraging data from ZYBRESTAT program at Glaucoma and Retinopathies 2010 conference

WSJ: Study on eye medicine reveals possible savings for Medicare

ACT awarded patent for production processes of RPE cells from hESCs

Final results from Visudyne Phase IIIb DENALI study presented at World Ophthalmology Congress

SQNM first-quarter 2010 total revenues up 22%: MicroStockProfit.com

Bevacizumab effective for treatment of wet AMD: Study

USPTO grants ISCO patent to International Stem Cell's hpSC

Ranibizumab improves vision in patients with visual impairment due to DME: RESTORE study

Adeona completes 50% enrollment in Part 2 CopperProof-2 study of oral zinc cysteine for Alzheimer's Disease

New book to prevent Age-Related Macular Degeneration

Results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 to be presented at ASCO 2010

MUHC's Henry C. Witelson Ocular Pathology Laboratory celebrates tenth anniversary

Resolvyx presents new data on RX-10001 for corneal herpes simplex virus infection at ARVO 2010

Pfizer presents data on in vivo activity of PF-04523655 siRNA drug candidate at ARVO annual meeting

StemCells first-quarter total revenue up 307%

Acucela to present data on ACU-4429 oral visual cycle modulator for dry AMD at Retina International meeting

Report shows increasing rates of AMD among Asians

Latinos have higher rates of developing visual impairment than non-Hispanic whites: Researchers

IRIDEX commences commercial shipment of IQ 532 laser systems

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News